Skip to main content
SpringerLink
Log in

Can PET–CT with FDG replace contrast enhanced CT for imaging of liver metastases?

  • Editorial commentary
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006;10:982–9.

    Article  Google Scholar 

  2. Cancer. World Health Organization [February 2006]. Retrieved on 2007-05-24.

  3. Colon Cancer, Adenocarcinoma. http://www.emedicine.com/med/topic413.htm

  4. Strauss LG, Clorius JH, Schlag P, Lehner B, Kimmig B, Engenhart R, et al. Recurrence of colorectal tumours: PET evaluation. Radiology 1989;170:329–32.

    PubMed  CAS  Google Scholar 

  5. Minn H, Soini I. 18F-fluorodeoxyglucose scintigraphy in diagnosis and follow-up of treatment in advanced breast cancer. Eur J Nucl Med 1989;15:61–6.

    Article  PubMed  CAS  Google Scholar 

  6. Chua SC, Groves AM, Kayani I, Menezes L, Gacinovic S, Du Y, et al. The impact of 18F-FDG PET–CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 2007; xx:xx–xx.

    Google Scholar 

  7. Wiering B, Krabbe PF, Jager GJ, Oyen WJG, Ruers TJM. The impact of fluor-18-deoxyglucose positron emission tomography in the management of colorectal liver metastases. Cancer 2005;104:2658–70.

    Article  PubMed  Google Scholar 

  8. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, et al. Value of positron emission tomography with F-18-fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 2002;20:388–95.

    Article  PubMed  CAS  Google Scholar 

  9. Bipat S, van Leeuwen MS, Comans EF, Pijl ME, Bossuyt PM, Zwinderman AH, et al. Colorectal liver metastases. CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005;237:123–31.

    Article  PubMed  Google Scholar 

  10. Rappeport ED, Loft A, Bertheisen AK, von der Recke P, Larsen PN, Mogensen AM, et al. Contrast-enhanced FDG–PET/CT vs. SPIO-enhanced MRI vs. FDG–PET vs CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 2007;48:369–78.

    Article  PubMed  CAS  Google Scholar 

  11. Sahani DV, Kalva SP, Fischman AJ, Kadavigere R, Blake M, Hahn PF, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 2005;185:239–47.

    PubMed  Google Scholar 

  12. Strauss L, Bostel F, Clorius JH, Raptou E, Wellman H, Georgi P. Single-photon emission computed tomography (SPECT) for assessment of hepatic lesions. J Nucl Med 1982;23:1059–65.

    PubMed  CAS  Google Scholar 

  13. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992;16:684–89.

    Article  PubMed  CAS  Google Scholar 

  14. Strauss LG, Klippel S, Pan L, Schönleben K, Haberkorn U, Dimitrakopoulou-Strauss A. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging 2007; 34:868–77.

    Article  PubMed  Google Scholar 

  15. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmacokinetics of 68Ga-DOTATOC and 18F-FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115–22.

    Article  PubMed  CAS  Google Scholar 

  16. Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Quantitative PET Studies in pretreated melanoma patients: a comparison of 6-18F-fluoro-l-dopa with 18F-FDG and 15O-water using compartment and noncompartment analysis. J Nucl Med 2001;42:248–56.

    PubMed  CAS  Google Scholar 

  17. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumours: comparison with 18F-FDG. J Nucl Med 2007;48:1245–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical PET Group–Biological Imaging (E0601), Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, 69120, Germany

    Ludwig G. Strauss & Antonia Dimitrakopoulou-Strauss

Authors
  1. Ludwig G. Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonia Dimitrakopoulou-Strauss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ludwig G. Strauss.

Additional information

This Editorial commentary refers to the article http://dx.doi.org/10.1007/s00259-007-0518-y.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strauss, L.G., Dimitrakopoulou-Strauss, A. Can PET–CT with FDG replace contrast enhanced CT for imaging of liver metastases?. Eur J Nucl Med Mol Imaging 34, 1902–1905 (2007). https://doi.org/10.1007/s00259-007-0619-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0619-7

Search

Navigation